Klinische Protokolle

Vollständige Verfahrensrichtlinien von der Vorbeurteilung bis zur Nachsorge

Zuletzt aktualisiert: May 27, 2026Geprüft von: Andrei Dokukin, MDStufe 2 — Klinische Evidenz (off-label)

FDA-aligned clinical protocolsOff-label expansion guidance

Klinische Evidenz — nicht FDA-bewertet

Diese Protokolle fassen veröffentlichte klinische Richtlinien, systematische Übersichtsarbeiten und institutionelle Best Practices zusammen. Behandler müssen sie an ihr spezifisches klinisches Setting anpassen und die geltenden Gesetze zum staatlichen Tätigkeitsumfang einhalten. Jede Hirudotherapie muss von zugelassenen Gesundheitsanbietern oder unter deren Aufsicht durchgeführt werden.

Kapitel 22: Klinische Protokolle — Vollständige Referenz

Diese Seite präsentiert den vollständigen Rahmen klinischer Protokolle für die medizinische Blutegeltherapie und umfasst die Einrichtung der Räumlichkeiten, die Beurteilung vor dem Eingriff, die Anwendungstechnik, Überwachung, Versorgung nach dem Eingriff, Komplikationsmanagement und Dokumentation. Jede Schwelle, Dosis und jeder Algorithmus stammt aus peer-reviewter Evidenz und Expertenkonsens (Mumcuoglu 2014; Whitaker 2012; Herlin 2017; Michalsen 2003, 2008, 2018).

Die medizinische Blutegeltherapie (Hirudo verbana) ist ein FDA 510(k)-zugelassenes Verfahren unter Verwendung eines 510(k)-zugelassenen Medizinprodukts (Kategorie unklassifiziert Pre-Amendment). Erfolgreiche klinische Ergebnisse hängen von der strikten Einhaltung standardisierter Protokolle in jeder Phase ab: Vorbereitung der Einrichtung, Patientenbeurteilung, Blutegel-Auswahl und -Anwendung, intraoperative Überwachung, Wundversorgung nach dem Eingriff, Antibiotikaprophylaxe und Komplikationsmanagement. Diese Seite bietet die vollständige Verfahrensreferenz.

Schlüsselprinzipien

Sterilitäts-Paradox: Das Verfahren verwendet einen lebenden Organismus mit einem obligaten Darmsymbionten (Aeromonas hydrophila). Die Infektionsprävention beruht auf Antibiotikaprophylaxe, nicht allein auf steriler Technik.
Blutverlust ist kumulativ: Jeder Blutegel entfernt 15-65 mL. Serielle mikrochirurgische Protokolle (3-6 Blutegel q4h × 5 Tage) können 2-5 Liter kumulativen Blutverlust verursachen. 49,75% der mikrochirurgischen Patienten benötigen eine Transfusion (Whitaker 2012).
Einwilligung ist kritisch: Die informierte Einwilligung ist der Bereich mit dem höchsten medizinrechtlichen Risiko. Patienten müssen die Y-förmige Bissnarbe, die 4- bis 24-stündige Blutung, das 7-20% Infektionsrisiko ohne Prophylaxe und die Transfusionsmöglichkeit verstehen.
Niemals gewaltsam ziehen: Gewaltsame Entfernung birgt Risiken der Aeromonas-Regurgitation in die Wunde, Zahnausriss und Gewebetrauma.
Alles dokumentieren: Checkliste vor dem Eingriff, SOAP-Notizen, Anordnungen nach dem Eingriff und Entlassungsanweisungen bilden einen rechtlich verteidigungsfähigen medizinischen Datensatz.

Anforderungen an Einrichtung und Ausrüstung

Spezifikationen für den Eingriffsraum

Parameter	Spezifikation	Begründung
Temperature	22–25°C (72–77°F)	Leeches become sluggish below 20°C; above 25°C increases metabolic stress
Lighting	Bright, adjustable overhead	Precise site visualization; dimming for patient comfort during wait
Ventilation	Adequate airflow; no fragrances	Leeches refuse attachment in presence of perfumes, disinfectant fumes, or strong odors
Surfaces	Nonporous, easily disinfected	Blood and body fluid cleanup; OSHA compliance
Sink access	Handwashing station within room	Hand hygiene before/after; water for leech handling
Patient positioning	Adjustable chair or examination table	Patient must remain comfortable for 30–90 minutes; recline capability for vasovagal

Ausrüstungsliste (19 Artikel)

#	Artikel	Spezifikation	Geschätzte Kosten (USD)
1	FDA-cleared medicinal leeches	Hirudo verbana; suppliers: Ricarimpex (France), Biopharm (UK), Carolina Biological (US)	$10–15/leech
2	Storage containers	Glass jars, 1–3L, wide-mouth	$5–15
3	Dechlorinated water	Bottled spring water or tap water aged 24h uncovered	$3–10
4	Aquarium thermometer	Submersible, range 10–30°C	$3–8
5	Nitrile examination gloves	Box of 100, nonlatex (latex may deter leeches)	$8–15
6	Blunt-tipped forceps	Stainless steel, for leech transfer (not grasping)	$5–10
7	Syringe guides	5–10 mL syringes with plunger removed; directs leech to precise site	$0.50 each
8	Sterile gauze pads	4×4 inch, non-woven; large quantity for post-detachment bleeding	$5–10/pack
9	Semi-permeable membrane	Thin barrier film to confine leeches to application zone	$5–15
10	Absorbent underpads	Disposable, waterproof backing, for bed/chair protection	$10–20/pack
11	Biohazard waste container	Red, leak-proof, biohazard labeled	$15–30
12	70% ethyl alcohol	500 mL; for euthanizing used leeches and detachment stimulation	$5–10
13	Medical tape	Hypoallergenic, paper or silk; for dressing securement	$3–5
14	Application window/ring	Adhesive barrier to restrict leech migration; optional	$5–10
15	Vital signs monitor	Blood pressure cuff, pulse oximeter, thermometer	$50–300
16	Timer	Digital timer for feeding duration and monitoring intervals	$5–10
17	Camera / phone	Clinical photography for wound documentation (with consent)	Existing
18	Sterile needle (25G)	For producing blood droplet to encourage attachment	$0.10 each
19	Emergency supplies kit	See Emergency Supplies section below	$200–500
Gesamte Anlaufkosten (ohne Blutegel)		$350-$1,000

Blutegel-Lagerung und Qualitätssicherung

Lagerprotokoll (8 Punkte)

Use glass jars (1–3L) with wide mouths — never plastic (chemical leaching)
Fill with dechlorinated water: bottled spring water OR tap water left uncovered 24 hours to off-gas chlorine
Change water every 3–4 days; inspect for turbidity, dead leeches, or mucus
Maximum density: 10 leeches per liter of water
Cover with 4-layer gauze secured by rubber band — leeches are strong escape artists
Store at 18–22°C (64–72°F); away from sunlight and vibration
No aromatic substances in storage area (perfumes, cleaning agents, hand sanitizer)
Never mix fed and unfed leeches — fed leeches release digestive enzymes; unfed leeches may cannibalize

Shelf life: Use within 30 days of receipt for optimal feeding activity and therapeutic efficacy.

Daily inspection: Check for lethargic or dead leeches (pale, non-responsive to touch); remove immediately.

Qualitätsindikatoren für therapie-bereite Blutegel (5 Kriterien)

Active swimming: Vigorous, sinusoidal movement when container is gently agitated
Firm body: Muscular tone when lifted with blunt forceps; not flaccid or bloated
Dark coloration: Healthy olive-green to dark brown dorsal surface; ventral lighter
Responsive to stimulation: Contracts rapidly when touched; anterior sucker actively explores
No visible lesions: No white patches, ulcers, swelling, or mucus coating

Ablehnungskriterien

Blutegel verwerfen, die lethargisch, blass, aufgebläht sind, weiße Flecken haben oder sich bei Stimulation nicht zusammenziehen. Keine Blutegel verwenden, die länger als 30 Tage gelagert wurden. Ein Blutegel, der sich weigert, sich an vorbereitete warme Haut mit einem Bluttröpfchen anzuheften, sollte ersetzt werden — nicht mit einem unwilligen Blutegel weitermachen.

Notfallausrüstung

Alle Notfallausrüstungen müssen vor Beginn der Blutegeltherapie sofort im Eingriffsraum zugänglich sein. Verfallsdaten monatlich überprüfen.

#	Artikel	Spezifikation	Zweck
1	Epinephrine autoinjector	0.3 mg IM (adult); 0.15 mg (pediatric)	Anaphylaxis first-line treatment
2	Diphenhydramine	50 mg IM injectable	Allergic reaction; adjunct to epinephrine
3	Silver nitrate sticks	75% silver nitrate / 25% potassium nitrate	Chemical cauterization of bleeding bite wounds
4	Topical thrombin / Gelfoam	Absorbable gelatin sponge or topical bovine thrombin	Hemostasis for refractory oozing
5	Suture kit	3-0 and 4-0 absorbable suture with needle driver	Figure-of-eight closure for refractory bleeding
6	Normal saline	500 mL bags (0.9% NaCl), ×2	Volume resuscitation, wound irrigation
7	Aminocaproic acid	Oral or IV formulation	Antifibrinolytic for refractory bleeding
8	Blood pressure cuff	Manual or automatic, multiple cuff sizes	Hemodynamic monitoring
9	Pulse oximeter	Fingertip, with alarm capability	Continuous oxygenation monitoring
10	IV access supplies	18G and 20G catheters, tubing, tape, tourniquet	Rapid vascular access for resuscitation
11	Oxygen delivery	Nasal cannula + non-rebreather mask; portable O2 tank	Respiratory support for anaphylaxis/vasovagal
12	Albuterol inhaler	MDI with spacer	Bronchospasm management in allergic reaction

Geschätzte Kosten: $200-500 für ein komplettes Notfallkit. Verfallsdaten bei der monatlichen Ausrüstungsprüfung überprüfen.

Beurteilung vor dem Eingriff

Patientenanamnese-Screening

Eine gezielte Anamnese mit Schwerpunkt auf Blutungsrisiko, Infektionsanfälligkeit und früherer Blutegelexposition ist vor Therapiebeginn wesentlich. Die folgenden 7 Erkrankungen erfordern eine spezifische Bewertung:

Erkrankung	Screening-Fokus	Maßnahme
Bleeding disorders	Hemophilia, von Willebrand, thrombocytopenia, liver-related coagulopathy	Hematology consult; may be absolute CI if severe
Hepatic disease	Cirrhosis, synthetic dysfunction, portal hypertension	Check PT/INR, albumin; coagulopathy risk
Renal disease	CKD stage, dialysis, uremic platelet dysfunction	Check BMP, bleeding time; dose-adjust antibiotics
Immunocompromised	HIV/AIDS, transplant, chemotherapy, biologics, chronic steroids	Do NOT hold immunosuppressants; increase infection surveillance
Cardiovascular disease	Anticoagulation status, prosthetic valves, recent MI/stent	Coordinate med hold with cardiology; bridge if needed
Diabetes mellitus	Type, HbA1c, neuropathy, peripheral vascular disease	Increased infection risk; impaired wound healing; closer follow-up
Prior leech therapy	Previous reactions, allergy, infection, sensitization	IgE sensitization possible; if prior anaphylaxis = absolute CI

Allergie-spezifisches Screening

Antibiotika-Allergien

Speziell nach Fluorchinolon- (Cipro) und Sulfonamid- (TMP-SMX) Allergien fragen — dies sind die beiden Erstlinien-Prophylaktika. Reaktionstyp (Hautausschlag vs. Anaphylaxie) dokumentieren, um die Auswahl der Alternative zu leiten.

Blutegel-SGS-Allergie

Jucken tritt bei 37-75% der Patienten auf (keine Allergie). Echte IgE-vermittelte Reaktionen gegen hirudin und andere Speichelproteine sind selten, aber dokumentiert. Frühere Anaphylaxie auf Blutegeltherapie ist eine absolute Kontraindikation.

Latex-Allergie

Ausschließlich Nitrilhandschuhe verwenden. Latexhandschuhe in der Nähe der Anwendungsstelle können Rückstände übertragen, die die Blutegel-Anhaftung hemmen und eine Patientenreaktion auslösen.

Aktuelle Anamnese (HPI): Spezifische Indikation für die Blutegeltherapie, relevante chirurgische Anamnese (Replantation, Lappentyp, Zeitpunkt) und aktuellen Status des behandelten Gewebes/Gelenks dokumentieren.

Überlegungen zu älteren Patienten (>65 Jahre)

Ältere Patienten erfordern aufgrund altersbedingter physiologischer Veränderungen, die die Behandlungssicherheit und -ergebnisse beeinflussen, zusätzliche Beurteilung und Überwachung vor dem Eingriff.

Beurteilung vor dem Eingriff

Comprehensive medication review: Document all anticoagulants, antiplatelets, NSAIDs, and supplements (fish oil, vitamin E, ginkgo). Polypharmacy is common in elderly patients and significantly increases bleeding risk.
Renal function assessment: Calculate CrCl (Cockcroft-Gault) for antibiotic dosing. Fluoroquinolone prophylaxis requires dose adjustment if CrCl <50 mL/min. Ciprofloxacin: 250 mg BID if CrCl 30–50; avoid if <30.
Baseline hematology: CBC with differential, INR/aPTT, BMP. Lower transfusion threshold (Hgb <8 g/dL in patients with cardiovascular disease). Type and screen for patients on serial protocols.
Skin integrity assessment: Age-related skin thinning increases wound healing time and scarring risk. Document skin condition at application site. Consider reduced leech numbers per session.
Cardiovascular assessment: Evaluate for orthostatic hypotension risk, especially with anticipated blood loss. Heart failure patients may have reduced blood volume tolerance.

Anpassungen der Überwachung

More frequent vital signs: Q2h (vs standard Q4h) during active treatment, especially in patients with cardiovascular comorbidities.
Lower intervention thresholds: Consider transfusion at Hgb <8 g/dL (vs <7 in younger patients), particularly in patients with coronary artery disease.
Extended post-procedure observation: Minimum 2 hours post-detachment (vs 1 hour standard) due to delayed recognition of symptoms in elderly patients.
Fall prevention: Assess mobility and balance before discharge. Ensure caregiver availability for first 24 hours post-treatment.
Wound care education: Provide written instructions with large font. Confirm understanding with teach-back method. Engage caregiver in discharge education.

Laboranforderungen

Test	Zweck	Handlungsschwelle	Maßnahme
CBC (Complete Blood Count)	Baseline hemoglobin/hematocrit and platelet count	Hgb <8 g/dL; Plt <50,000/µL	Hgb <8: transfuse before proceeding. Plt <50K: relative CI — hematology consult, weigh risk/benefit
PT / INR	Coagulation status (warfarin, liver disease)	INR >3.0; INR 2.0–3.0	INR >3.0: hold warfarin, recheck, do not proceed. INR 2.0–3.0: proceed with caution, extra hemostasis supplies
aPTT	Intrinsic pathway / heparin monitoring	>2× upper limit of normal	Investigate cause; consider heparin hold or reversal; consult hematology
Type & Screen	Blood bank readiness for transfusion	Required for all surgical/inpatient	49.75% of microsurgical patients require transfusion (Whitaker 2012). Must be current (<72h)
BMP (Basic Metabolic Panel)	Renal function baseline; electrolyte status	Cr >2.0 or GFR <30	Dose-adjust renally cleared antibiotics; closer monitoring of fluid balance in multi-day protocols
Blood Cultures	Rule out active sepsis if febrile	T >38.0°C or clinical suspicion	Active sepsis = absolute contraindication to leech therapy. Treat infection first.

Ambulante Ausnahme

Für ambulante muskuloskelettale Einzelsitzungs-Anwendungen (2-8 Blutegel): Blutbild + PT/INR sind bei gesunden Patienten ohne Blutungsanamnese oder Antikoagulanzien-Anwendung ausreichend. Typ und Screening, aPTT, BMP und Blutkulturen sind für ambulante Sitzungen mit geringem Volumen nicht routinemäßig erforderlich.

Medikamentenmanagement

Antikoagulanzien, Thrombozytenaggregationshemmer und NSAIDs erhöhen das Blutungsrisiko erheblich. Die folgenden Pausenpläne balancieren das Blutungsrisiko gegen das thromboembolische Risiko. Hinweis: 54,29% der mikrochirurgischen Protokolle verwenden begleitende Antikoagulation (Whitaker 2012) — Medikamentenpausen gelten möglicherweise nicht in chirurgischen Rettungskontexten.

Wirkstoffklasse	Beispiele	Pausenzeit	Anmerkungen
Warfarin	Coumadin	Hold 3–5 days	Target INR <2.0 for elective; bridge with LMWH if high thrombotic risk (mechanical valve, recent DVT)
DOACs	Rivaroxaban, apixaban, dabigatran, edoxaban	Hold 24–48h	Shorter half-life than warfarin; 48h for dabigatran if CrCl <50; reversal agents available (idarucizumab, andexanet)
Heparin (IV UFH)	Unfractionated heparin drip	Hold 4–6h	Check aPTT before proceeding; protamine available for reversal
LMWH	Enoxaparin, dalteparin	Hold 12–24h	12h for prophylactic dose; 24h for therapeutic dose; partial protamine reversal
Aspirin	ASA 81–325 mg	Do NOT routinely hold (surgical); Hold 7 days (elective)	Irreversible COX-1 inhibition; in microsurgical salvage, aspirin is often deliberately continued for antiplatelet effect
Clopidogrel	Plavix	Hold 5–7 days	Irreversible P2Y12 inhibition; coordinate with cardiology if recent stent (<12 months)
NSAIDs	Ibuprofen, naproxen, diclofenac, ketorolac	Hold 3–5 days pre-procedure	Reversible COX inhibition; also avoid post-procedure for 48h (prolongs bleeding from hirudin's anticoagulant effect)
Immunosuppressants	Tacrolimus, mycophenolate, methotrexate, biologics	Do NOT hold	Holding risks rejection/flare. Instead: increase infection surveillance, lower threshold for empiric antibiotics, closer wound monitoring

Informierte Einwilligung

Die informierte Einwilligung ist das größte Berufshaftpflicht-Risiko in der Blutegeltherapie. Die Dokumentation muss umfassend, unterzeichnet und alle unten genannten Elemente enthalten. Eine nur mündliche Einwilligung ist unzureichend.

Erforderliche Einwilligungs-Elemente

Art des Verfahrens

Live FDA 510(k)-cleared medical devices (Hirudo verbana)
Leeches attach via tripartite jaw producing a characteristic Y-shaped bite mark
Feeding duration: 20–45 minutes per leech (up to 60–90 min for large leeches)
Leeches inject saliva containing hirudin (anticoagulant) and other bioactive compounds
Post-detachment oozing is expected and therapeutic (continued decompression)

Erwartete Vorteile

Venous decongestion and improved tissue perfusion
Tissue/flap salvage (78% overall salvage rate; Whitaker 2012)
Pain reduction in musculoskeletal conditions
Local anti-inflammatory and analgesic effects via salivary compounds

Alternativen zur Blutegeltherapie

Heparin-soaked gauze (passive decompression)
Surgical revision / re-exploration
Hyperbaric oxygen therapy (HBO)
Negative pressure wound therapy (NPWT)
Observation and expectant management
Patient may refuse treatment at any time

Häufige Nebenwirkungen (erwartet)

Nebenwirkung	Häufigkeit	Dauer
Post-detachment bleeding/oozing	100%	4 to 24 hours (normal)
Mild sting/pinch at attachment	~100%	30 seconds to 2 minutes
Itching at bite site	37–75%	1–14 days; may be delayed
Local hematoma / ecchymosis	Common	5–14 days
Y-shaped bite scar	100%	Permanent; 2–3 mm; fades over months
Regional lymphadenitis	6–13%	Days to weeks; self-limiting

Schwerwiegende Risiken (Müssen offengelegt werden)

Risiko	Rate	Details
Aeromonas infection	7–20% (without prophylaxis)	Prophylactic antibiotics reduce risk to <5%. Infection drops tissue salvage from 88% to 37.4%
Transfusion requirement	49.75% (surgical series)	Cumulative blood loss in serial protocols. Type & screen required for surgical patients
Allergic reaction / anaphylaxis	Rare (<1%)	IgE sensitization to leech SGS proteins; may occur on re-exposure
Treatment failure	22%	78% overall salvage rate; failure increases with infection, delay, and arterial insufficiency

Blutegel-Auswahl und Dosierung nach Indikation

Auswahlkriterien

Größenauswahl

Small (3–5 cm): Delicate areas — digits, ears, eyelids, pediatric
Standard (6–10 cm): Most indications — flaps, joints, general use
Large (>10 cm): Heavy decompression — large flaps, extensive congestion

Aktivitätsbeurteilung

Vigorous swimming when agitated
Rapid contraction when touched
Active exploration with anterior sucker
Firm muscular body tone

Hungerverifikation

Flat, non-distended body (not recently fed)
Actively seeking warm objects/skin
Unfed for minimum 2–4 weeks (supplier standard)
Never use a leech that has previously fed on a patient

Indikationsspezifisches Dosierungsprotokoll

Indikation	Standarddosis	Bereich	Häufigkeit	Kontext
Digit replantation	1–2	1–3	Every 2–4 hours	FDA-cleared; small leeches; serial application days 1–5
Ear replantation	1–2	1–3	Every 2–4 hours	FDA-cleared; small leeches; delicate tissue handling
Free flap (head/neck)	2–4	1–6	Every 2–8 hours	FDA-cleared; standard leeches; assess tissue color between sessions
DIEP/TRAM breast flap	2–3	1–4	Every 4–8 hours	FDA-cleared; standard to large leeches; larger surface area
Knee osteoarthritis	4–6	4–8	Single treatment	Periarticular placement; RCT-supported (Michalsen 2003, n=51)
Thumb CMC-1 OA	2–3	2–3	Single treatment	Small leeches; periarticular (Michalsen 2008, n=32)
Lateral epicondylitis	2–4	2–4	Single treatment	Over lateral epicondyle (Backer 2011, n=52)
Chronic low back pain	4–7	4–7	Single treatment	Paravertebral bilateral placement (Michalsen 2018, n=44)

Schattierte Zeilen = FDA 510(k)-zugelassene mikrochirurgische Indikationen.

Blutverlust-Schätzung

Each leech removes approximately 15–65 mL total: 5–15 mL during active feeding + 10–50 mL post-detachment oozing (anticoagulant effect of injected hirudin). For a single session with 6 leeches, anticipate 90–390 mL total blood loss.

Serial microsurgical protocol: 3–6 leeches every 4 hours × 5 days = potential cumulative blood loss of 2–5 liters. This is why 49.75% of microsurgical patients require transfusion (Whitaker 2012). Hematocrit monitoring every 4–8 hours is mandatory.

Vorbereitung der Stelle und Anwendungstechnik

Vorbereitung der Stelle (5 Schritte)

Clean with warm water only — NO alcohol, betadine, chlorhexidine, or any antiseptic. Chemical residues prevent leech attachment and may be toxic to the leech.
Shave hair if present — Leeches cannot attach through hair; clip or shave a 5 cm radius around each intended site.
Mark application sites — Use a surgical skin marker to indicate exact placement points. Essential for documenting bite locations and ensuring symmetric placement.
Apply application window (optional) — An adhesive ring or barrier film around the target area prevents leech migration to unintended sites. Especially useful for facial or periorbital application.
Protect surrounding areas — Absorbent underpads beneath the treatment area. Barrier drapes to prevent leech escape. Warm the skin if ambient temperature is low (warm moist gauze for 2–3 minutes).

Standard-Anwendungsmethode (5 Schritte)

Don nitrile gloves; have forceps, gauze, and containment supplies within reach
Transfer selected leech(es) from storage jar to a small clean container using blunt forceps
Invert the small container directly over the prepared application site; leech drops onto skin
Leech attaches within 30 seconds to 5 minutes — confirmed by rhythmic body contractions (peristaltic feeding movements)
Cover feeding leech loosely with moist gauze (3–4 layers) to maintain humidity and prevent desiccation; do not compress

Spritzenführungsmethode (Präzise Platzierung)

Remove plunger from a 5–10 mL syringe. Place leech inside the barrel with anterior (head) end toward the open tip.
Press syringe tip firmly against skin at the exact target point. The confined space directs the leech to attach at the precise location.
Once attached (rhythmic contractions visible), gently slide syringe barrel away. Optionally, pulling the plunger creates mild negative pressure to encourage engorgement.

Am besten geeignet für: Finger, Ohren, kleine Lappen, Bereiche nahe kritischer Strukturen (Augen, Öffnungen) oder wenn präzise Platzierung im Millimeterbereich erforderlich ist.

Fehlerbehebung bei Anhaftungsverweigerung

Warm the skin with a moist warm gauze compress for 2–3 minutes (increases blood flow to surface)
Prick the skin with a sterile 25G needle to produce a small blood droplet at the target site
Try a different leech — some individual leeches are more responsive than others
Ensure no chemical residues on skin (alcohol, soap, perfume, antiseptic)
Check room temperature (must be 22–25°C) and absence of strong odors

Bedrohliches Zeichen

Eine anhaltende Weigerung mehrerer Blutegel, sich an einer chirurgischen Stelle (Lappen oder Replantat) trotz warmer Haut und Bluttröpfchen anzuheften, kann auf nicht lebensfähiges Gewebe mit unzureichender Perfusion hinweisen. Dies ist ein diagnostischer Befund, der eine dringende chirurgische Neubewertung veranlassen sollte.

Einen nahrungsaufnehmenden Blutegel NIEMALS gewaltsam ziehen

Die gewaltsame Entfernung eines angehefteten Blutegels birgt Risiken: (1) Regurgitation des Darminhalts einschließlich <em>Aeromonas hydrophila</em> direkt in die Wunde, (2) Ausriss von Kieferteilen, die im Gewebe eingebettet sind und chirurgische Entfernung erfordern, und (3) Gewebetrauma an der Bissstelle. Stimulationstechniken anwenden (alkoholgetränkte Baumwolle nahe der anterioren Saugscheibe) oder auf natürliche Ablösung warten.

Intraoperative Überwachung

Chirurgische/Stationäre Überwachung (6 Parameter)

Parameter	Häufigkeit	Schwelle / Maßnahme
Vital signs (HR, BP, SpO2, Temp)	Every 30 min during active feeding	Tachycardia >100, SBP <90, SpO2 <92%: reassess and intervene
Tissue assessment	Every 30 min (color, turgor, cap refill, Doppler)	Worsening congestion despite therapy: increase leech frequency or number; persistent arterial insufficiency: surgical re-exploration
Hematocrit / Hemoglobin	Every 4–8 hours	Transfuse if Hgb <7 g/dL (or <8 in CAD patients). 49.75% will need transfusion
Leech feeding status	Continuous visual observation	Detachment before 20 min: tissue may lack adequate perfusion. Failure to engorge: try different leech or reassess tissue viability
Post-detachment bleeding	Every 1–2 hours for first 6 hours	Count saturated gauze pads; >10 pads in 4 hours = activate bleeding algorithm
Pain assessment (NRS 0–10)	Every 2 hours	Score >5: acetaminophen 1000 mg PO/IV. Avoid NSAIDs. Score >7: consider opioid rescue

Ambulante/Muskuloskelettale Überwachung (3 Parameter)

Parameter	Zeitpunkt	Maßnahme
Vital signs	Before and after procedure	Document baseline and post-procedure; hold discharge if SBP <100 or symptomatic orthostasis
Pain (NRS)	Before, during, and 30 min after	Report sustained >5/10 after procedure. Document pain trajectory for efficacy assessment
Bleeding status	At detachment and 30 min post	Ensure manageable oozing before discharge; patient must demonstrate dressing management

Nahrungsaufnahmedauer und Ablösung

Dauer

Typical feeding: 20–45 minutes
Large leeches / heavy congestion: 60–90 minutes
Engorgement: 5–10× original body weight when fully sated
Leech detaches spontaneously when sated — do not rush

Ablösungstechniken (Falls vorzeitiger Abbruch erforderlich)

Natural: Wait for spontaneous detachment (preferred)
Stimulation: Gently touch cotton swab moistened with 70% alcohol or vinegar near (not on) the anterior sucker
Salt/alcohol: Place a few grains of table salt or a drop of alcohol adjacent to the head end
NEVER: Pull, twist, burn, or apply substances directly onto the leech body

Entsorgungsprotokoll (6 Schritte)

Immediately place detached leech into 70% ethyl alcohol — euthanasia within minutes
Transfer euthanized leech to red biohazard waste container
Seal container when full; label with date and contents
Dispose through regulated medical waste stream per OSHA 29 CFR 1910.1030
Never reuse a leech that has fed on a patient (blood-borne pathogen transmission risk)
Never flush or dispose in sinks, toilets, or regular trash

Wundversorgung nach dem Eingriff

Sofortiges Wundmanagement (5 Schritte)

Apply clean dry gauze (4×4) directly over each bite site — do NOT apply direct pressure (oozing is therapeutic for venous decompression)
Layer additional absorbent pads over the initial gauze — expect significant saturation over 4–10 hours
Secure with medical tape or light wrap — no compression bandaging (compression defeats the purpose of continued oozing)
When blood saturates dressing, ADD layers on top — do NOT remove the underlying dressing for 24 hours (removing disrupts early clot formation)
Place absorbent underpads beneath the treatment area to protect bedding/clothing — especially important for overnight

Wundpflegeanweisungen für den Patienten (6 Punkte)

Expect oozing through bandages for 4 to 24 hours — this is normal and expected
Add fresh gauze on top of saturated dressings; do not remove the bottom layer for 24 hours
After 24 hours: gently remove dressing, clean with warm water and mild soap only
Apply a clean dry dressing; change daily for 3–5 days until wound is dry
Do not apply hydrogen peroxide, alcohol, betadine, or antibiotic ointment to bite wounds
Keep the treatment area elevated above heart level when possible to reduce bleeding

Blutungs-Zeitleiste

Normales Blutungsmuster

0–2 hours: Active oozing, gauze saturates rapidly
2–6 hours: Gradual slowing; oozing continues but rate decreases
6 to 24 hours: Gradual cessation of oozing; dressings less saturated
10–24 hours: Complete cessation; wound begins to crust

Besorgniserregende Blutung (Algorithmus aktivieren)

Persistent brisk bleeding beyond 10 hours
Saturating >10 gauze pads (4×4) in 4 hours
Hemodynamic changes: tachycardia, hypotension, dizziness, syncope
Visible pulsatile bleeding (arterial — rare but emergent)
Patient reports feeling faint or lightheaded

Blutungs-Zeitleiste

Serielle mikrochirurgische Protokolle (3-6 Blutegel q4h × 5 Tage) können 2-5 Liter kumulativen Blutverlust verursachen. Hämatokrit muss alle 4-8 Stunden überprüft werden. Transfundieren, wenn Hgb <7 g/dL (oder <8 bei Patienten mit koronarer Herzkrankheit). 49,75% der Patienten in der systematischen Übersichtsarbeit von Whitaker 2012 benötigten eine Transfusion.

Antibiotikaprophylaxe

Die Antibiotikaprophylaxe muss mindestens 1 Stunde vor dem Ansetzen des ersten Blutegels begonnen und während des Behandlungszyklus sowie 24-48 Stunden nach der letzten Blutegelanwendung fortgesetzt werden. Ohne Prophylaxe betragen die Aeromonas-Infektionsraten 7-20%; mit Prophylaxe sinken die Raten auf <5% (0% in Nguyen 2012, n=39).

Erstlinien-Therapieschemata

Therapieschema	Wirkstoff	Dosis	Verabreichungsweg	Dauer
Preferred (Herlin 2017)	Ciprofloxacin + TMP-SMX DS	500 mg BID + 160/800 mg BID	PO	Through treatment + 24–48h after last leech
Monotherapy option A	Ciprofloxacin alone	500 mg BID	PO	Through treatment + 24–48h
Monotherapy option B	TMP-SMX DS alone	160/800 mg BID	PO	Through treatment + 24–48h

Alternative Therapieschemata (allergiebasiert)

Allergie / Kontraindikation	Alternatives Therapieschema	Dosis	Verabreichungsweg
Fluoroquinolone allergy	TMP-SMX DS alone	160/800 mg BID	PO
Sulfonamide allergy	Ciprofloxacin alone	500 mg BID	PO
Both FQ + sulfa allergy	Ceftriaxone	1 g daily	IV
Pediatric patients	TMP-SMX pediatric dosing	4 mg/kg TMP + 20 mg/kg SMX BID	PO

Resistenzwarnung

Ciprofloxacin-Resistenz wurde bei bis zu 43% der Aeromonas-Umweltisolate dokumentiert (Giltner 2013). Plasmidvermittelte Chinolon-Resistenz (PMQR)-Gene wurden bei 42% der Süßwasser-Aeromonas-Spezies gefunden. Dies ist die primäre Begründung für eine duale Prophylaxe (Cipro + TMP-SMX) statt Ciprofloxacin-Monotherapie.

Vermeiden: Cephalosporine der 1. Generation (intrinsische Aeromonas-Resistenz über chromosomale Beta-Lactamasen). Amoxicillin/Ampicillin (schlechte Aktivität gegen Aeromonas).

Chargen-Überwachungsprotokoll (Institutionen, die >50 Blutegel/Monat verwenden)

On receipt: Culture 1 leech per batch (sacrifice for gut swab) — aerobic culture specifically requesting Aeromonas identification and susceptibilities
Every 30 days: Culture 1 leech from each active storage container to monitor for resistance drift during storage
Record results in institutional antibiogram specific to leech-sourced Aeromonas — track cipro, TMP-SMX, ceftriaxone, meropenem, and gentamicin susceptibilities
Adjust empiric prophylaxis based on batch-specific resistance patterns — if cipro resistance >20% in batch, switch to TMP-SMX monotherapy or add second agent
Report MDR isolates to the leech supplier, infection control committee, and state public health department if resistance to ≥3 classes is identified

Schmerzmanagement und Jucken

Schmerzmanagement-Protokoll

First-line: Acetaminophen 500–1000 mg PO q6h (max 4g/day); effective for mild-moderate post-procedure pain
AVOID NSAIDs for 48 hours post-procedure: Ibuprofen, naproxen, and ketorolac inhibit platelet function and prolong the anticoagulant effect of injected hirudin, significantly increasing bleeding duration
AVOID aspirin for 7 days post-procedure: Irreversible COX-1 inhibition compounds leech-induced anticoagulation
Moderate-severe pain: Opioid rescue — oxycodone 5 mg PO q4-6h PRN or tramadol 50 mg PO q6h; short course only
Surgical patients: IV acetaminophen 1000 mg q6h; PCA if multi-day protocol with significant pain

Juckreiz-Management

Jucken an der Bissstelle tritt bei 37-75% der Patienten auf. Dies ist eine lokale histaminvermittelte Reaktion auf Speichelproteine, in den meisten Fällen KEINE allergische Reaktion. Der Beginn kann unmittelbar oder um 2-7 Tage verzögert sein.

Oral antihistamine: Cetirizine 10 mg daily (non-sedating) or diphenhydramine 25–50 mg q6h PRN (sedating)
Topical steroid: Hydrocortisone 1% cream applied to bite sites after 24 hours only (do not apply to actively oozing wounds)
Cool compress: 10–15 minutes PRN for symptomatic relief
Do NOT scratch: Risk of secondary bacterial infection of bite wounds

Algorithmus für übermäßige Blutung

Ein 5-stufiger eskalierender Ansatz für Blutungen nach Ablösung. Die meisten Blutungen klingen mit Schritten 1-2 ab. Die Progression zu Schritt 5 ist selten, erfordert aber sofortige Ressourcen.

Schritt 1 — Beurteilung

Characterize bleeding: brisk flow vs. slow ooze
Count saturated gauze pads per hour
Check vital signs: HR, BP, orthostatics if ambulatory
Check most recent hematocrit; order STAT if >4h old
Review medications (anticoagulants, antiplatelets, NSAIDs)
Normal: Oozing for 4 to 24 hours post-detachment is expected and does not require intervention

Schritt 2 — Konservative Maßnahmen

Add additional gauze layers; apply firm direct pressure for 15–20 minutes (timed)
Elevate the treatment area above heart level
Review and hold any anticoagulants/antiplatelets if clinically safe
Apply ice pack wrapped in cloth adjacent to (not directly on) wound

Schritt 3 — Topische Hämostatika

Silver nitrate stick: Apply directly to the bite wound for chemical cauterization (5–10 seconds per wound)
Topical thrombin: Apply directly to oozing wound surface
Absorbable gelatin sponge (Gelfoam): Pack into the Y-shaped bite wound and apply gentle pressure

Schritt 4 — Nahtverschluss

Figure-of-eight suture through the Y-shaped bite wound using 3-0 or 4-0 absorbable suture
This is definitive local hemostasis for refractory bite-site bleeding
Consider aminocaproic acid (antifibrinolytic) if diffuse oozing from multiple sites
Order STAT CBC, PT/INR, aPTT, fibrinogen
Establish IV access if not already present

Schritt 5 — Hämodynamische Instabilität (selten)

IV crystalloid: Normal saline 500–1000 mL bolus for volume resuscitation
Type & crossmatch: Order immediately if not already current
Transfuse: pRBC if Hgb <7 g/dL (or <8 in CAD). FFP if INR >1.5. Platelets if <50K and actively bleeding
Discontinue leech therapy until hemodynamically stable and coagulopathy corrected
Hematology consult for refractory coagulopathy or DIC workup
Surgical consult if arterial bleeding suspected or local measures fail

49.75% of microsurgical patients require transfusion during leech therapy courses (Whitaker 2012). This is an expected complication, not a failure of technique.

Aeromonas-Infektionsalgorithmus

Aeromonas hydrophila ist das primäre infektiöse Risiko und macht 88% aller infektiösen Komplikationen aus. Beginn: 24 Stunden bis 10 Tage (bis zu 26 Tage). Infektion reduziert die Gewebe-Rettung von 88,3% auf 37,4% (Whitaker 2012).

Schritt 1 — Erkennung (7 klinische Anzeichen)

Expanding erythema >2 cm beyond bite site borders (mark and track)
Purulent or seropurulent drainage from bite wounds
Increasing pain after 48 hours (pain should be decreasing by this point)
Fever >38.0°C / 100.4°F
Regional lymphadenopathy (palpable tender nodes in draining basin)
Tissue necrosis or color change at or near bite sites
Systemic signs: rigors, tachycardia, hypotension, elevated WBC/CRP

Schritt 2 — Sofortige Maßnahmen

Wound culture: Aerobic swab; specifically request Aeromonas identification and full susceptibilities
Blood cultures ×2: If systemic signs (fever, tachycardia, hypotension)
Labs: CBC with differential, CRP, BMP, lactate if sepsis concern
Clinical photography: Document wound appearance; mark erythema borders with skin marker and timestamp
Escalate prophylactic antibiotics to empiric treatment doses (see table below)

Schritt 3 — Empirische Antibiotikatherapie (nach Schweregrad)

Schweregrad	Kriterien	Therapieschema	Verabreichungsweg
Mild	Local signs only; no systemic symptoms; stable vitals	Ciprofloxacin 500 mg BID + TMP-SMX DS BID	PO
Moderate	Spreading cellulitis; low-grade fever; elevated WBC	Ceftriaxone 1g daily + Ciprofloxacin 400 mg q12h	IV
Severe / Sepsis	High fever; hemodynamic changes; tissue necrosis; bacteremia	Meropenem 1g q8h + Gentamicin 5 mg/kg daily	IV

Schritt 4 — Kulturgerichtete Anpassung

Narrow antibiotics based on culture susceptibilities (typically available 48–72h)
If MDR (multi-drug resistant): escalate to carbapenems (meropenem, imipenem)
Monitor resistance patterns; update institutional antibiogram
ID (Infectious Disease) consultation for MDR isolates or treatment failure

Schritt 5 — Chirurgische Intervention

Debridement: Required if tissue necrosis develops; may require serial debridement
Emergent flap revision: If infection threatens the primary surgical reconstruction
Critical statistic: Infection drops tissue salvage from 88.3% to 37.4% — early, aggressive treatment is essential
Plastic surgery / microsurgery consultation mandatory for infected flaps

Zeitverlauf: Typischer Beginn 24 Stunden bis 10 Tage nach der Therapie; verzögerte Präsentationen bis zu 26 Tage wurden dokumentiert. Hohen Verdachtsindex während des gesamten Nachsorge-Zeitraums aufrechterhalten.

Protokoll für allergische Reaktion

Dreistufiges eskalierendes Protokoll basierend auf dem Schweregrad der Reaktion. Die meisten Reaktionen sind lokal (Jucken/Erythem an der Bissstelle) und erfordern keinen Therapieabbruch.

Stufe 1 — Lokale Reaktion (am häufigsten)

Lokalisiertes Jucken, Erythem oder Urtikaria auf die Bissstelle und unmittelbare Umgebung beschränkt.

Maßnahme	Details
Oral antihistamine	Cetirizine 10 mg PO or diphenhydramine 25–50 mg PO
Topical steroid	Hydrocortisone 1% cream after 24h (not on open wound)
Cold compress	15 minutes PRN; cloth barrier between ice and skin
Documentation	Record reaction type and treatment in chart
Future therapy	NOT a contraindication — premedicate with antihistamine for future sessions

Stufe 2 — Generalisierte Reaktion

Diffuse Urtikaria, Angioödem fernab der Bissstelle, generalisiertes Jucken, GI-Symptome oder milde respiratorische Symptome.

Maßnahme	Details
Discontinue therapy	Remove any remaining leeches using alcohol stimulation; do not force-pull
Diphenhydramine	50 mg IM (faster onset than PO)
Methylprednisolone	125 mg IV push (prevents biphasic reaction)
Observation	Minimum 4 hours monitoring for progression or biphasic reaction
Future therapy	Relative contraindication — allergy/immunology referral before considering retreatment

Stufe 3 — Anaphylaxie

Hypotonie, Bronchospasmus, Larynxödem, kardiovaskulärer Kollaps, Bewusstlosigkeit.

Maßnahme	Details
1. Epinephrine	0.3 mg IM (anterolateral thigh); repeat q5–15 min PRN
2. Emergency code	Call 911 / activate code team; position patient supine with legs elevated
3. IV access	2 large-bore IVs (16–18G); NS 1–2L rapid infusion
4. Oxygen	High-flow O2 via non-rebreather mask (15 L/min)
5. Antihistamines	Diphenhydramine 50 mg IV + famotidine 20 mg IV (H1 + H2 blockade)
6. Bronchospasm	Albuterol 2.5 mg nebulized; repeat q20 min PRN
7. Steroids	Methylprednisolone 125 mg IV (prevents biphasic)
8. Disposition	ICU admission for monitoring minimum 12–24 hours
Future therapy	ABSOLUTE CONTRAINDICATION to future leech therapy

Konsultations-Auslöser

Szenario	Konsultieren	Maßnahme / Schwelle
Hgb <7 g/dL (or <8 in CAD)	Blood bank / Transfusion medicine	Transfuse pRBC; type & crossmatch; reassess leech therapy frequency
Refractory bleeding (Step 4–5)	Hematology	Coagulopathy workup; DIC screen; reversal agents; aminocaproic acid
Suspected Aeromonas infection	Infectious Disease	Culture-directed therapy; MDR management; antibiogram review
Tissue necrosis or flap compromise	Plastic Surgery / Microsurgery	Surgical debridement; flap revision; vascular re-exploration
Anaphylaxis or severe allergic reaction	Allergy/Immunology + ICU	Acute management per Tier 3 protocol; future leech therapy CI evaluation
INR >3.0 or aPTT >2x normal	Hematology / Cardiology	Anticoagulation management; bridge therapy; reversal consideration
Persistent leech refusal (surgical)	Primary surgical team	Tissue viability assessment; Doppler evaluation; consider surgical re-exploration
Pediatric patient	Pediatrics	Weight-based dosing for antibiotics and analgesics; smaller leech selection; parental consent
Elderly patient (>65 years)	Geriatrics / Primary Care	Polypharmacy review (anticoagulants, antiplatelets); renal dose adjustment for antibiotics (CrCl-based); reduced blood volume tolerance; baseline CBC with lower transfusion threshold; fall risk assessment if ambulatory

Nachsorge-Plan

Zeitpunkt	Beurteilung	Maßnahmen
24 hours	Wound status; bleeding cessation; vital signs	Remove initial dressing; clean wounds; photograph. CBC if surgical/inpatient. Confirm antibiotics ongoing
72 hours (3 days)	Wound healing; infection screening; anemia	Assess for erythema, drainage, warmth (Aeromonas onset peak). Repeat CBC if serial protocol. Photograph wounds
1 week	Wound healing trajectory; delayed infection	Clinical photograph for record. Assess for late infection signs. Evaluate pain/function improvement (MSK patients). Suture removal if placed
2 weeks	Final wound assessment; scarring	Wounds should be fully epithelialized. Assess Y-shaped scar formation. Document final wound status photograph
4 weeks	Scar maturation; late infection surveillance	Late Aeromonas infection can present up to 26 days post-therapy. Final scar assessment. Functional outcome evaluation for MSK patients. Case closure documentation

Dokumentation: Checkliste vor dem Eingriff

Vor Beginn der Blutegelanwendung ausfüllen. Alle Punkte müssen überprüft und dokumentiert werden.

Patientenscreening

Indication for leech therapy documented

Bleeding disorder screening completed (hemophilia, vWD, thrombocytopenia, hepatic coagulopathy)

Hepatic/renal function assessed

Immune status evaluated (immunosuppressants, HIV, transplant)

Cardiovascular history / anticoagulation status reviewed

Diabetes screening (type, HbA1c, neuropathy)

Prior leech therapy history obtained (reactions, infections, sensitization)

Allergieüberprüfung

Fluoroquinolone (ciprofloxacin) allergy: YES / NO — type: ___________

Sulfonamide (TMP-SMX) allergy: YES / NO — type: ___________

Leech saliva / hirudin allergy: YES / NO

Latex allergy: YES / NO (use nitrile gloves regardless)

Labor

CBC obtained — Hgb: ___ g/dL Plt: ___K Date: ___

PT/INR obtained — INR: ___ Date: ___

Type & Screen current (<72h) [surgical/inpatient only]

BMP obtained [multi-day protocols]

Blood cultures drawn if febrile (active sepsis = absolute CI)

Medikamente und Einwilligung

Anticoagulant/antiplatelet medications reviewed; holds coordinated if applicable

Prophylactic antibiotics ordered and administered BEFORE first leech

Written informed consent obtained and signed (see Consent section)

Patient verbalized understanding of Y-scar, bleeding, infection risk, transfusion possibility

Ausrüstungsüberprüfung

Room temperature 22–25°C confirmed

Leeches inspected (quality criteria met, <30 days since receipt)

Emergency supplies present and in-date

Vital signs monitor functional

Biohazard container available; 70% ethanol for euthanasia

Dokumentation: SOAP-Notiz zum Eingriff

S — Subjektiv

Chief Complaint / Indication: [venous congestion of ___ flap / knee OA pain / etc.]

Pain Level (Pre-procedure): NRS ___/10

Patient Understanding: Consent reviewed; patient verbalizes understanding of procedure, risks, alternatives, and right to refuse.

Relevant HPI: [surgical date, flap type, current tissue status, symptom duration]

O — Objektiv

Vital Signs (Pre): BP ___/___ HR ___ SpO2 ___% Temp ___°C

Labs: Hgb ___ g/dL Plt ___K INR ___ aPTT ___

Site Assessment (Pre): [color, turgor, cap refill, Doppler, temperature, edema]

Leeches Applied: ___ leeches, size: ___ cm, to [anatomic location(s)]

Attachment Time: ___:___ to ___:___ (duration: ___ min each)

Feeding Behavior: [normal peristalsis / sluggish / refusal — if refusal, number tried]

Detachment: Spontaneous / Stimulated (method: ___)

Blood Loss Estimate: ___ mL (feeding + oozing)

Site Assessment (Post): [color improvement, bleeding status, tissue viability]

Vital Signs (Post): BP ___/___ HR ___ SpO2 ___%

Pain Level (Post): NRS ___/10

Photographs: Pre and post procedure images obtained: YES / NO

A — Beurteilung

Diagnosis: [Venous congestion of ___ flap, status post leech therapy session #___ / Knee OA, treated with leech therapy]

Response: [Improvement in tissue color/turgor/cap refill / Pain reduction from ___/10 to ___/10]

Complications: [None / Excessive bleeding / Refusal to attach / Allergic reaction — describe]

P — Plan

Next Session: [___ leeches in ___ hours / Single session complete]

Antibiotics: Continue cipro ___ mg BID + TMP-SMX DS BID × ___ days post-last leech

Monitoring: [Hct q___h / Vital signs q___min / Wound check q___h]

Pain: Acetaminophen ___ mg q___h PRN. Avoid NSAIDs × 48h.

Wound Care: Dry gauze dressing; do not remove × 24h; add layers if saturated

Follow-up: [24h wound check / 72h infection screen / 1 week assessment]

Disposition: [Remain inpatient for serial therapy / Discharge with instructions]

Dokumentation: Anordnungsset nach dem Eingriff

Kategorie	Anordnung
Activity	Bed rest with affected area elevated above heart level. Bathroom privileges with assistance. No ambulation unassisted × 4h post-procedure (orthostatic risk).
Diet	Regular diet. Encourage oral hydration ≥2L/day to support volume status. NPO if surgical re-exploration anticipated.
Medications — Antibiotics	Continue ciprofloxacin 500 mg PO BID + TMP-SMX DS PO BID. Duration: through treatment course + 24–48h after last leech.
Medications — Pain	Acetaminophen 1000 mg PO/IV q6h scheduled (max 4g/day). PRN: oxycodone 5 mg PO q4-6h for pain >5/10. AVOID NSAIDs × 48h, aspirin × 7 days.
Medications — Itching	Cetirizine 10 mg PO daily PRN itching. Diphenhydramine 25–50 mg PO q6h PRN severe itching (warn: sedation). Hydrocortisone 1% cream to bite sites after 24h.
Monitoring — Vitals	q30min during active feeding; q2h × 6h post-detachment; q4h thereafter (inpatient). Pre/post only (outpatient).
Monitoring — Labs	CBC q4–8h (serial inpatient protocol). STAT CBC if bleeding concerns or hemodynamic changes.
Transfusion	Type & Screen current. Transfuse pRBC for Hgb <7 g/dL (or <8 if CAD). FFP if INR >1.5 with active bleeding. Platelets if <50K with active bleeding.
Wound Care	Dry gauze dressing over bite sites; do not remove × 24h. Add gauze layers over saturated dressing. Absorbent underpads under treatment area. No compression wraps.
Notification Triggers	Notify physician for: HR >100 or <50; SBP <90; SpO2 <92%; Temp >38°C; Hgb <7; bleeding saturating >10 pads/4h; rash/urticaria; signs of anaphylaxis; patient distress.
Discharge Criteria (Outpatient)	Vitals stable; bleeding manageable; patient demonstrates dressing management; written discharge instructions provided; antibiotic prescription in hand; follow-up scheduled within 72h.

Dokumentation: Entlassungsanweisungen für den Patienten

In schriftlicher Form bei der Entlassung bereitstellen. Einfache, dem Lese- und Schreibniveau des Patienten angemessene Sprache verwenden.

Blutung — Was ist normal

Your bite wounds will ooze blood for 4 to 10 hours after the leeches are removed. This is normal and expected.
The bleeding will gradually slow down and stop completely within 12–24 hours.
Add clean gauze pads on top of your bandage if it becomes soaked. Do NOT remove the bottom layer for 24 hours.
Place a towel or absorbent pad under the treated area to protect your bedding and clothing.

Antibiotika — Sehr wichtig

Take ALL prescribed antibiotics exactly as directed. Do not skip doses.
Continue antibiotics for the full course, even if you feel fine.
Antibiotics prevent a specific bacterial infection (Aeromonas) that lives in the leech.
Take with food if you experience nausea. If you develop a rash, hives, or difficulty breathing, stop the medication and call your doctor or go to the ER immediately.

Schmerzmanagement

Take acetaminophen (Tylenol) for pain: 500–1000 mg every 6 hours as needed (max 4000 mg/day).
Do NOT take ibuprofen (Advil/Motrin), naproxen (Aleve), or aspirin for at least 48 hours — these increase bleeding.
If prescribed a stronger pain medication, use it only as directed.

Jucken

Itching at the bite sites is very common (happens in up to 75% of patients) and is NOT an allergic emergency.
Take cetirizine (Zyrtec) 10 mg daily or diphenhydramine (Benadryl) 25–50 mg every 6 hours.
After 24 hours, you may apply hydrocortisone 1% cream to the bite sites.
Do not scratch the bite sites — this can cause infection.

Nachsorgetermine

72 hours (3 days): Wound check and infection screening
1 week: Healing assessment and photographs
2 weeks: Final wound evaluation
Keep all scheduled appointments even if everything seems fine

Sofort in die Notaufnahme gehen, wenn:

Bleeding that will not stop after 10 hours of firm pressure
Soaking through more than 10 gauze pads in 4 hours
Feeling faint, dizzy, lightheaded, or having a racing heartbeat
Fever above 100.4°F (38°C)
Increasing redness, swelling, warmth, or pus at the bite sites (especially after 48 hours)
Red streaks spreading from the bite sites
Rash, hives, swelling of face/throat, or difficulty breathing

Über Ihre Narben

Each leech leaves a small Y-shaped mark approximately 2–3 mm in size. These marks are initially red but will fade over several months to become faint, pale scars. They are permanent but typically barely noticeable once fully healed. Avoid sun exposure to healing bite sites for 3–6 months to minimize scar darkening.

Evidenzzusammenfassung

Die folgende Tabelle fasst die wichtigsten Studien zusammen, die diese klinischen Protokolle informieren. Die Evidenz umfasst systematische Übersichtsarbeiten, randomisierte kontrollierte Studien, prospektive Kohorten und Expertenkonsens-Richtlinien.

Evidenzbasis klinischer Protokolle — Schlüsselstudien
Studie	Design	Population (n=)	Intervention	Primäres Outcome	Ergebnis
Whitaker et al. 2012	Systematic review	Plastic/reconstructive surgery patients across 67 publications (1966-2009) (n=277)	Leech therapy with variable prophylaxis (79% received antibiotics)	Infection rate, salvage rate, transfusion rate	78% overall salvage; 49.75% transfusion rate; infection drops salvage from 88.3% to 37.4% Landmark review. 14.4% infection rate. 21.8% overall complication rate. 54.29% used concomitant anticoagulation
Herlin et al. 2017	Systematic review + retrospective cohort	Free flap patients requiring leech therapy (n=49)	Ciprofloxacin + TMP-SMX dual prophylaxis	Infection rate and flap salvage	83.7% salvage; low infection rate with dual therapy Established cipro + TMP-SMX as "most relevant" prophylaxis regimen
Michalsen et al. 2003	Randomized controlled trial	Patients with symptomatic knee osteoarthritis (n=51)	Single session of 4 leeches applied periarticular	Pain (VAS), function (WOMAC), at 7 and 28 days	Significant pain reduction sustained at 28 days; NNT 2–3 at day 7 First RCT of leech therapy for OA; seminal study
Michalsen et al. 2008	Randomized controlled trial	Patients with thumb carpometacarpal (CMC-1) osteoarthritis (n=32)	2-3 leeches applied to CMC-1 joint, single session	Pain, function, and grip strength at 7 and 28 days	Significant improvement in pain and function vs. topical diclofenac
Michalsen et al. 2018	Randomized controlled trial	Patients with chronic low back pain (n=44)	4-7 leeches applied paravertebral, single session	Pain (VAS), disability (ODI), at 28 days	Clinically significant pain reduction vs. back-care education control
Backer et al. 2011	Randomized controlled trial	Patients with lateral epicondylitis (tennis elbow) (n=52)	2-4 leeches applied to lateral epicondyle, single session	Pain (VAS), grip strength, DASH score at 7 and 28 days	Significant pain reduction and functional improvement vs. topical diclofenac
Giltner et al. 2013	Case report + genomic analysis	Patient with ciprofloxacin-resistant Aeromonas infection post-leech therapy (n=1)	Culture-directed antibiotic therapy after cipro failure	Clinical course and resistance mechanism identification	Cipro resistance confirmed; PMQR genes identified; successful treatment with alternative agents Highlighted need for dual-agent prophylaxis and batch surveillance
Palm et al. 2022	Institutional protocol study	High-volume leech therapy center (>50 leeches/month) (n=NR)	Batch culture surveillance protocol for incoming leech shipments	Antibiotic resistance patterns and protocol compliance	Identified variable resistance patterns between batches; informed empiric prophylaxis selection Model for institutional surveillance programs
Mumcuoglu et al. 2014	Expert consensus + literature review	Practitioners of medicinal leech therapy across all indications (n=NR)	Detailed clinical recommendations for leech use	Standardized protocols for selection, application, monitoring, and disposal	Published definitive best-practice guidelines covering facility, technique, and safety Most-cited procedural reference for medicinal leech therapy
Lineaweaver et al. 1992	Multicenter case series	Replantation and flap surgery patients with Aeromonas infection (n=10)	Documentation of post-leech Aeromonas infections across centers	Infection timing, severity spectrum, and tissue outcomes	Onset 24h to >10 days; severity from minor wound to tissue loss/sepsis Established the mandate for routine antibiotic prophylaxis
Nguyen et al. 2012	Prospective case series	Patients receiving leech therapy with standardized prophylaxis protocol (n=39)	Universal prophylactic antibiotics per standardized protocol	Aeromonas infection rate	0% infection rate (0/39 patients) Demonstrated that standardized prophylaxis can eliminate Aeromonas infection
Sig et al. 2017	Meta-analysis	Patients with knee osteoarthritis across RCTs and comparative studies (n=237)	Leech therapy (4-8 leeches, single or repeated sessions)	Pooled pain reduction (VAS) and function (WOMAC)	Statistically significant pain reduction (SMD -1.05) and functional improvement Strongest pooled evidence for musculoskeletal leech therapy

Wichtige Erkenntnisse

Klinische Grundlagen

Antibiotics before first leech: Ciprofloxacin 500 mg BID + TMP-SMX DS BID is the standard of care. Without prophylaxis, Aeromonas infection rates are 7–20%.
Never force-pull: Forcible removal risks Aeromonas regurgitation into the wound, tooth avulsion, and tissue trauma.
Blood loss is cumulative: 15–65 mL per leech. Serial protocols may cause 2–5 liters cumulative loss. 49.75% of surgical patients need transfusion.
Consent is the highest legal risk: Document nature, benefits, common side effects (6), serious risks (4 with statistics), and alternatives (5).
No antiseptics on application site: Clean with warm water ONLY. Alcohol, betadine, and chlorhexidine prevent attachment.

Überwachung und Sicherheit

Hematocrit q4–8h in serial surgical protocols. Transfuse at Hgb <7 (or <8 in CAD).
Cipro resistance up to 43%: Dual-agent prophylaxis is recommended. Batch surveillance for institutions using >50 leeches/month.
Aeromonas onset up to 26 days: Maintain infection surveillance through the 4-week follow-up visit.
Itching is not allergy: 37–75% incidence. Treat with antihistamines. True anaphylaxis is rare (<1%) but requires permanent contraindication.
Avoid NSAIDs × 48h, aspirin × 7 days: Both prolong the anticoagulant effect of injected hirudin and increase bleeding risk.

Forschungs- und Bildungshinweis

Die Informationen auf dieser Seite werden ausschließlich zu Bildungs- und Informationszwecken bereitgestellt und stellen keine medizinische Beratung, Diagnose oder Behandlungsempfehlung dar. Die klinischen Evidenzzusammenfassungen geben die veröffentlichte, peer-reviewte Literatur wieder und implizieren keine therapeutische Wirksamkeit außerhalb FDA-zugelassener Kontexte.

Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt. Anwendungen im Untersuchungs- und Off-label-Bereich werden als solche durchgehend gekennzeichnet. Praktiker sollten vor der klinischen Anwendung die aktuellen FDA-Richtlinien, institutionelle Protokolle und geltende bundesstaatliche Vorschriften konsultieren.

ASH unterstützt eine rigorose, evidenzbasierte Bewertung aller Hirudotherapie-Anwendungen durch kontrollierte klinische Studien und peer-reviewte Forschung.